What is Omeros's gross profit margin?

What is the market's earnings forecast for Omeros next quarter?

Did Omeros beat or miss consensus estimates last quarter?

What is Omeros's latest dividend and current dividend yield?

What were the key takeaways from Omeros’s earnings call?

What does Omeros do and what are its main business segments?

What guidance did Omeros's management provide for the next earnings period?

What is the revenue and EPS growth rate for Omeros year over year?

- **$2.1B Deal Milestone**: Zaltenibart sale to Novo Nordisk includes $240M upfront, $410M development milestones, and high-teens royalties.
- **YARTEMLEA Launch Success**: 30% of top 80 transplant centers have formulary approval; 24-hour drug delivery meets urgent patient needs.
- **Financial Strength**: $171.8M cash, debt-free except $70.8M convertible notes. YARTEMLEA expected to be self-sustaining in 2026, cash flow positive by 2027.
- **Clinical Impact**: First treatment for TA-TMA with no safety restrictions, reducing infection risks vs. C5 inhibitors.

**【CEO Summary Section】**
- **Landmark Deal with Novo Nordisk**: Sold zaltenibart for $240 million upfront, with potential $2.1 billion in milestones and royalties. Novo will develop and commercialize zaltenibart globally.
- **FDA Approval of YARTEMLEA**: First treatment for TA-TMA, priced at $36,000 per vial. Early sales began within 3 weeks of approval, with 24-hour delivery to patients.
- **Commercial Launch Progress**: 30% of top 80 transplant centers have formulary approval. 70% of patients receive weekly dosing, with 30% on twice-weekly regimens.
- **Financial Health**: $171.8 million cash as of Q4 2025. Repaid $67.1 million term loan and $17.1 million convertible notes. Expect YARTEMLEA to be self-sustaining in 2026, cash flow positive by 2027.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Net income $86.5 million ($1.22/share), driven by $237.6 million gain from Novo deal. Non-GAAP adjusted net income $222.5 million ($3.14/share).
- **Cash Position**: $171.8 million, up $135.7 million from Q3. Repaid all debt except $70.8 million convertible notes.
- **2026 Outlook**: Operating expenses stable, R&D costs reduced via Novo reimbursement. Sales and marketing expenses to increase for YARTEMLEA launch.

**【Q&A Key Highlights】**
- **Formulary Progress**: 30% of top 80 centers have P&T approval. Remaining approvals expected to accelerate as payers approve all pre-authorization requests.
- **Dosing Patterns**: 70% weekly, 30% twice-weekly (pediatric bias). Field force educating on twice-weekly dosing benefits.
- **Third-Party Reimbursement**: All pre-authorization requests approved. HEOR analysis shows cost-effectiveness.
- **EMA and Ex-U.S. Strategy**: Mid-2026 EMA decision for YARTEMLEA. Exploring ex-U.S. partnerships for broad or regional commercialization.

Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript

- **$2.1B Strategic Deal**: Novo Nordisk collaboration provides $240M upfront and $100M near-term milestones.
- **Financial Turnaround**: Reduced debt by 80% to $17.1M; 2027 cash flow positive.
- **YARTEMLEA Launch**: FDA approval expected Q4; NTAP coverage secured.
- **Pipeline Expansion**: MASP-2 antibody (Phase 2), PDE7, and T-CAT programs advancing.

**【CEO Summary Section】**
- Announced a strategic collaboration with Novo Nordisk valued at up to $2.1 billion, including $240 million upfront payment and $100 million near-term milestones.
- Repositioned balance sheet with $36.1 million cash on hand and secured $20 million in debt repayment through the Novo transaction.
- YARTEMLEA (narsoplimab) FDA approval expected in Q4 2025 with commercial launch preparations finalized across 15+ transplant centers.
- Expanded pipeline includes MASP-2 antibody (OMS1029), PDE7, and T-CAT platforms, with Phase 2 studies initiated.

**【CFO Financial Commentary】**
- Q3 2025 net loss of $30.9 million ($0.47/share) vs. Q2 loss of $25.4 million ($0.43/share).
- Adjusted cash burn of $22 million, with $20 million raised through registered direct offering.
- Projected 2027 cash flow positivity post-Novo transaction.
- Repaid $67.1 million term loan and $17.1 million convertible notes, reducing debt by 80%.

**【Q&A Highlights】**
- FDA approval decision for YARTEMLEA expected in Q4; NTAP coverage discussions underway.
- Formulary access agreements secured with 75% of high-volume transplant centers.
- Historical control analysis validates YARTEMLEA's 30% survival benefit vs. standard care.
- 2026 operating expenses projected to increase 15% for launch-related costs.
- Novo collaboration excludes Omeros' MASP-2 small molecule programs, maintaining pipeline control.

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

- **Financial Resilience**: $20.6 million raise and debt restructuring extend runway, reducing near-term obligations by $100+ million.
- **Narsoplimab Milestones**: FDA PDUFA date extended to December 26, 2025; EMA MAA under review. Launch prep underway with 175-target transplant centers.
- **Pipeline Progress**: Zaltenibart Phase III paused; OMS1029 and OncotoX AML advancing. Potential multibillion-dollar partnership in advanced stages.
- **Market Differentiation**: Narsoplimab's safety profile positions it as superior to C5 inhibitors, with strong payer and physician interest.

**【CEO Summary Section】**
- **Financial Overview**: Q2 2025 net loss of $25.4 million ($0.43 per share), compared to $33.5 million ($0.58) in Q1. Cash and investments as of June 30: $28.7 million, with a $20.6 million net raise from a July registered direct offering.
- **Balance Sheet Strengthening**: Reduced 2026 convertible notes from $98 million to $17 million, eliminated a $20 million mandatory term loan prepayment, and extended debt maturity to 2029. These actions reduced near-term obligations by over $100 million.
- **Narsoplimab Regulatory Progress**: BLA for TA-TMA resubmitted in March, PDUFA date extended to December 26, 2025. MAA submitted to EMA in June, with a decision expected mid-2026. FDA indicated labeling discussions could begin by October.
- **Launch Readiness**: Expanded access program shows narsoplimab's safety and efficacy, with sales team targeting 175 transplant centers. Payers and physicians express strong interest due to narsoplimab's differentiated safety profile compared to C5 inhibitors.
- **Pipeline Updates**: OMS1029 (long-acting MASP-2 inhibitor) ready for Phase II restart; Zaltenibart (MASP-3 inhibitor) Phase III paused; PDE7 inhibitor OMS527 in preclinical for cocaine use disorder; OncotoX AML program advancing to IND.

**【CFO Financial Commentary】**
- **Q2 Financials**: Operating expenses from continuing operations: $32.4 million (down $2.6 million from Q1). R&D focused on narsoplimab and Zaltenibart. Interest expense: $3.9 million (Q2) vs. $3.7 million (Q1), driven by higher 2029 notes interest.
- **Debt Management**: 2026 notes reduced to $17.1 million, with capped call retaining $92.6 million potential value. Interest and other income: $1.2 million (Q2) vs. $1.1 million (Q1). Noncash gain from financial instruments: $8.2 million.
- **Future Outlook**: Q3 2025 operating expenses expected lower due to reduced clinical spending. Interest expense: ~$9.2 million (excluding noncash adjustments). Discontinued operations income: $5-7 million (excluding OMIDRIA adjustments).

**【Q&A Highlights】**
- **Launch Timing**: If approved in December, launch in Q1 2026. Adequate supply for several years. Field team ready for immediate deployment post-approval.
- **FDA Requests**: Additional analyses led to PDUFA delay. FDA collaboration remains positive, with no major deficiencies identified.
- **Partnerships**: Discussions on asset licensing, with one multibillion-dollar transaction in advanced stages. Proceeds could repay term loan, cover 12+ months of operations, and fund future milestones.
- **Market Response**: Physicians eager for narsoplimab due to high unmet need in TA-TMA. Expanded access program data reinforces safety and efficacy, contrasting with C5 inhibitors' infection risks.

Omeros (OMER)-14 Aug 25-2025 Q2 Earnings call transcript

- **Debt Restructuring Success**: Reduced near-term debt by $100M, extending maturity to 2029, and lowering interest burden.
- **Narsoplimab Clinical Triumph**: 3x survival improvement in TA-TMA, with FDA BLA resubmission on track for 9/25/25 approval.
- **Market Focus Shift**: Prioritizing narsoplimab launch and Zaltenibart cost management, with PNH market potential at $10B by 2032.
- **Financial Discipline**: Q1 R&D expenses down 0.7%, with $52.4M cash post-restructuring to support key programs.


**【CEO Overview】**
- **Financial Health**: Q1 2025 net loss of $33.5M ($0.58/share), with $52.5M cash on hand. Debt restructuring reduced near-term obligations by $100M, extending maturity to 2029.
- **Debt Restructuring**: Exchanged $71M of 2026 convertible notes for 2029 notes, plus $10M equity conversion, lowering 2026 notes to $17M.
- **Pipeline Priorities**: Narsoplimab (TA-TMA) FDA BLA resubmission accepted with 9/25/25 PDUFA date; Zaltenibart (PNH) Phase III paused due to capital constraints.
- **Narsoplimab Clinical Data**: Hazard ratio 0.32 (p < 0.0001), 3x survival improvement vs control. Expansion of EAP data manuscripts submitted for publication.
- **Market Potential**: TA-TMA estimated at $1B annually; PNH market projected to $10B by 2032.

**【CFO Financial Breakdown】**
- **Q1 2025 Results**: R&D expenses $35M (down $0.7M QoQ), interest expense $3.7M (up $0.5M QoQ). OMIDRIA royalties $6.7M (down 34% QoQ due to U.S. sales decline).
- **Liquidity**: $52.4M cash post-debt exchange. 2029 notes interest rate 9.5%, with $150M ATM facility available.
- **Q2 Outlook**: Operating expenses expected to decline as Zaltenibart trials pause. Interest expense ~$7.6M, income from discontinued ops $6-7M.

**【Q&A Highlights】**
- **Launch Readiness**: Narsoplimab prelaunch activities include commercial infrastructure build, EAP suspension to reduce costs, and focus on FDA engagement for 9/25 approval.
- **Patient Access**: TA-TMA ICD-10 codes ensure narsoplimab is only approved treatment, creating reimbursement barriers for off-label use. EAP for current patients continues, but new requests paused.
- **Capital Strategy**: Actively pursuing partnerships for nondilutive funding, with disciplined cost management across R&D and G&A.


Omeros (OMER)-15 May 25-2025 Q1 Earnings call transcript

- **narsoplimab TA-TMA BLA resubmission**: FDA PDUFA date set for Sept 2025; data shows 3x+ survival benefit (p < 0.00001) vs external controls.
- **Zaltenibart PNH Phase 3**: Head-to-head trials vs eculizumab/ravulizumab; 2025 data readout targeting $10B+ market.
- **Financial stability**: $90M cash on hand; debt restructuring & partnership discussions underway to extend runway.

**【CEO Financial Overview】**
- Q4 2024 net loss: $31.4 million ($0.54/share), narrowing from Q3 2024 ($32.2 million). Full-year 2024 net loss: $156.8 million ($2.70/share). 
- Cash & investments as of Dec 31, 2024: $90 million.
- Debt restructuring: Preliminary discussions to refinance 2026 convertible notes; exploring partnerships for complement franchise (narsoplimab, zaltenibart, OMS1029).

**【narsoplimab TA-TMA Update】**
- BLA resubmitted to FDA in March 2025; PDUFA date set for September 2025.
- Key data highlights:
  - Primary analysis: 3x+ survival benefit (p < 0.00001), e-value 5.7 (low risk of confounding).
  - Expanded Access Program (EAP): 50% 1-year survival in refractory patients vs <20% historical rate.
- European MAA preparation underway; Germany & Austria as rapporteur countries.

**【Zaltenibart PNH Development】**
- Phase 3 trials comparing to eculizumab/ravulizumab in head-to-head designs:
  - Study 1: Patients naive to complement inhibitors.
  - Study 2: Switchover from suboptimal C5 inhibitor response.
- PNH market size: $3.9B (2023) → $10B+ (2032). Zaltenibart Phase 3 data expected Q4 2025.
- Key advantages: convenience (8-week dosing), safety profile, no patient compliance risks.

**【CFO Financial Details】**
- Q4 2024 operating expenses: $35.7 million (flat vs Q3 2024).
- Interest expense: $3.2 million (down $1M vs Q3), driven by $4.1M non-cash adjustment.
- OMIDRIA royalties: $10.1 million (Q4) → $9.3 million (Q3), reflecting $2.1M YoY decline.
- Q1 2025 outlook:
  - Operating expenses: ~Q4 2024 level.
  - Interest expense: ~$7.2 million (includes $4.1M non-cash adjustment).
  - Discontinued ops income: $7-8 million (excl. remeasurement adjustments).

Actual												-0.53	-0.61	-0.66	-0.6	-0.57	-0.46	-0.36	4.48	-0.53	-0.49	-0.28	2.05	-0.54	-0.59	-0.6	-0.15	-0.63	-0.97	-0.56	-0.54	-0.58	-0.43	-0.47
Forecast												-0.34	-0.586	-0.486	-0.6913	-0.528	-0.5779	-0.4713	0.1813	-0.6567	-0.63	-0.558	-0.5664	-0.5301	-0.57	-0.6141	-0.555	-0.561	-1.1376	-0.705	-0.7756	-0.5658	-0.5028	-0.4468	-0.57
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-55.88%	-4.10%	-35.80%	+13.21%	-7.95%	+20.40%	+23.62%	+2371.04%	+19.29%	+22.22%	+49.82%	+461.94%	-1.87%	-3.51%	+2.30%	+72.97%	-12.30%	+14.73%	+20.57%	+30.38%	-2.51%	+14.48%	-5.19%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	--	23.54M	13.53M	26.11M	10.63M	21.06M	28.82M	30.00M	30.84M	27.70M	10.10M	0	0	0	0	0	0	0	0	0	0	0	0	0	--
Forecast	--	--	--	--	--	--	--	--	--	--	--	30.43M	17.10M	20.82M	14.91M	20.53M	24.27M	27.96M	66.92M	10.21M	0	2.79M	0	0	0	0	0	0	0	0	0	400.00K	312.50K	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-22.66%	-20.87%	+25.41%	-28.72%	+2.60%	+18.77%	+7.31%	-53.91%	+171.24%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-100.00%	0.00%	0.00%

OMER

OMER fundamentals

OMER Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

OMER

OMER fundamentals

OMER Q4 2025 Earnings Preview

Earnings Call

OMER Earnings Call Summary for Q4/20254:00 PM on Mar 31, 2026

OMER Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

OMER Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

OMER Earnings Call Summary for Q1/20254:30 PM on May 15, 2025

OMER Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

You can ask Aime